| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.100.7.717 |
| P698 | PubMed publication ID | 10449693 |
| P50 | author | Elizabeth Barrett-Connor | Q37322423 |
| Marcia L. Stefanick | Q109542605 | ||
| P2093 | author name string | Cushman M | |
| Tracy RP | |||
| Legault C | |||
| Judd HL | |||
| Kessler C | |||
| Sakkinen PA | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| P304 | page(s) | 717-722 | |
| P577 | publication date | 1999-08-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study | |
| P478 | volume | 100 |
| Q38290322 | 17beta-Estradiol inhibits cytokine induction of the human E-selectin promoter |
| Q43992057 | A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women |
| Q46472560 | Adiponectin and endothelial markers in postmenopausal women taking oral or transdermal hormone therapy |
| Q36863000 | Age trends in estradiol and estrone levels measured using liquid chromatography tandem mass spectrometry in community-dwelling men of the Framingham Heart Study |
| Q36809773 | Anxiety disorders and inflammation in a large adult cohort |
| Q34329552 | Assessing the role of oestrogen in the prevention of cardiovascular disease |
| Q38719293 | Association between Urinary Phytoestrogens and C-reactive Protein in the Continuous National Health and Nutrition Examination Survey |
| Q34589796 | Association between dietary fiber and serum C-reactive protein |
| Q73246211 | Association between gender and in-hospital mortality after percutaneous coronary intervention according to age |
| Q33800888 | Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and women |
| Q43781831 | Association of C-reactive protein with markers of prevalent atherosclerotic disease |
| Q36602044 | Association of Serum Sex Hormones with Hemostatic Factors in Women On and Off Hormone Therapy: The Multiethnic Study of Atherosclerosis |
| Q73849738 | Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users |
| Q40375395 | Association of common CRP gene variants with CRP levels and cardiovascular events. |
| Q35844355 | Association of depressive disorders, depression characteristics and antidepressant medication with inflammation |
| Q42487474 | Association of endogenous hormones with C-reactive protein, fibrinogen, and white blood count in post-menopausal women |
| Q57910181 | Association of endogenous sex hormone with C-reactive protein levels in middle-aged and elderly men |
| Q34007712 | Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women. |
| Q43693246 | Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy |
| Q43659682 | Beyond the null hypothesis--do the HERS results disprove the estrogen/coronary heart disease hypothesis? |
| Q37976087 | Bioactive compounds with effects on inflammation markers in humans. |
| Q36533649 | Biochemical markers surrogating on vascular effects of sex steroid hormones |
| Q59827301 | Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative |
| Q28200344 | C-reactive protein (CRP)-lowering agents |
| Q28192240 | C-reactive protein and cardiovascular disease: a review of risk prediction and interventions |
| Q35562701 | C-reactive protein and cardiovascular disease: new insights from an old molecule |
| Q37428583 | C-reactive protein as a predictor of disease in smokers and former smokers: a review |
| Q96231569 | C-reactive protein gene rs1205 polymorphism is associated with low-grade chronic inflammation in postmenopausal women |
| Q35034809 | C-reactive protein gene variants: independent association with late-life depression and circulating protein levels |
| Q90727987 | C-reactive protein level in late-onset depression: A case-control study |
| Q24672855 | C-reactive protein: a critical update |
| Q35017905 | Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy? |
| Q28213284 | Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials |
| Q39175755 | Cardiovascular disease in women, is it different to men? The role of sex hormones |
| Q36334352 | Changes in postmenopausal hormone therapy use since 1988. |
| Q43061618 | Clinical significance of high-sensitivity C-reactive protein in cardiovascular disease |
| Q35575630 | Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events |
| Q40732072 | Coronary Artery Disease in Postmenopausal Women |
| Q34022283 | Coronary Heart Disease in Postmenopausal Women with Type II Diabetes Mellitus and the Impact of Estrogen Replacement Therapy: A Narrative Review. |
| Q28219483 | Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease |
| Q50864215 | Cross-sectional and longitudinal relationships between perceived stress and C-reactive protein in men and women. |
| Q24792867 | Debate: The potential role of estrogen in the prevention of heart disease in women after menopause |
| Q24792878 | Debate: The potential role of estrogen in the prevention of heart disease in women after menopause |
| Q30671838 | Did you know? Hormone Replacement Therapy and Heart Disease: Plausible Mechanisms and Observational Studies Yield to Hard Data |
| Q34053569 | Difference by sex but not by race/ethnicity in the visceral adipose tissue-depressive symptoms association: the Multi-Ethnic Study of Atherosclerosis |
| Q43892468 | Differential effect of oestrogen on post-exercise cardiac muscle myeloperoxidase and calpain activities in female rats |
| Q73298961 | Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women |
| Q40168434 | Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study |
| Q44512688 | Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women |
| Q46496031 | Direct comparison of dietary portfolio vs statin on C-reactive protein |
| Q73226857 | Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management |
| Q46497152 | Dobutamine stress cardiac magnetic resonance imaging to detect myocardial ischemia in women |
| Q31030851 | Does genotype and equol-production status affect response to isoflavones? Data from a pan-European study on the effects of isoflavones on cardiovascular risk markers in post-menopausal women |
| Q44430821 | Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis |
| Q44274319 | Effect of hormonal replacement therapy on C-reactive protein and cell-adhesion molecules in postmenopausal women |
| Q34717132 | Effect of hormone replacement therapy on cardiovascular outcomes: a meta-analysis of randomized controlled trials |
| Q44044419 | Effect of hormone replacement therapy on carotid arterial compliance in healthy postmenopausal women |
| Q44163420 | Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes |
| Q37563372 | Effect of hormone replacement therapy on inflammatory biomarkers. |
| Q44256357 | Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial |
| Q43852476 | Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina |
| Q42651100 | Effects of an herbal medication containing bee products on menopausal symptoms and cardiovascular risk markers: results of a pilot open-uncontrolled trial |
| Q34510978 | Effects of antihypertensive drugs on endothelial dysfunction: clinical implications |
| Q46268406 | Effects of drospirenone on cardiovascular markers in human aortic endothelial cells |
| Q73055289 | Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women |
| Q34727136 | Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation |
| Q44166478 | Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen |
| Q44111075 | Effects of hormone replacement therapy on blood platelets |
| Q36359547 | Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article |
| Q40632178 | Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women |
| Q45929033 | Effects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes. |
| Q43672800 | Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women |
| Q50912748 | Effects of the progestagen-only contraceptive implant Implanon on cardiovascular risk factors. |
| Q46813482 | Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer |
| Q34482114 | Effects of transdermal estrogen replacement therapy on cardiovascular risk factors |
| Q36383775 | Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women |
| Q89887221 | Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease |
| Q37306273 | Epidemiology of cytokines: the Women On the Move through Activity and Nutrition (WOMAN) Study |
| Q42521812 | Estradiol reduces basal and cytokine induced monocyte adhesion to endothelial cells |
| Q44410755 | Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size |
| Q74182465 | Estrogen and atherothrombosis |
| Q46851818 | Estrogen replacement raises rat CRP without evidence of complement activation |
| Q35181580 | Estrogens, progestogens and thrombosis |
| Q43546776 | Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study |
| Q31103663 | Female mice are protected against high-fat diet induced metabolic syndrome and increase the regulatory T cell population in adipose tissue |
| Q45075971 | Female sex hormones and uveitis |
| Q35109844 | Gender, hyperlipidemia, and coronary artery disease |
| Q42594950 | Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels--a study in twins |
| Q48002948 | Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family |
| Q39336336 | High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol |
| Q34973446 | High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment |
| Q40728614 | High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy |
| Q37857555 | High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus |
| Q37161550 | High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus |
| Q51681371 | Hormonal factors and respiratory health in women--a review. |
| Q44620741 | Hormonal replacement therapy and cardiovascular risk: contra-indication or non-indication? |
| Q39396170 | Hormone Replacement Therapy for Primary and Secondary Prevention of Heart Disease |
| Q35596294 | Hormone replacement therapy and cardioprotection: the end of the tale? |
| Q35918730 | Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease |
| Q34011174 | Hormone replacement therapy and cardiovascular risk |
| Q36144161 | Hormone replacement therapy and risk of acute myocardial infarction : a review of the literature. |
| Q34327242 | Hormone replacement therapy for prevention of coronary heart disease: current evidence |
| Q44660785 | Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women |
| Q36148637 | Hormone replacement therapy, body mass index and asthma in perimenopausal women: a cross sectional survey |
| Q36059933 | Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications |
| Q35647802 | Hormone therapies and vascular outcomes: who is at risk? |
| Q33231108 | Hormone therapy and cardiovascular disease: a systematic review and meta-analysis |
| Q34675309 | Hormones and heart disease: what we thought, what we have learned, what we still need to know |
| Q37586959 | Hypertension in pregnancy is associated with elevated C-reactive protein levels later in life |
| Q73355160 | Impact of hormonal deficit and cardiovascular risk factors on life expectancy in hypopituitarism |
| Q34928704 | Inflammation in end-stage renal disease: sources, consequences, and therapy |
| Q36427427 | Inflammatory biomarkers and cardiovascular risk: association or cause and effect? |
| Q35728222 | Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity |
| Q92624806 | Interaction between postmenopausal hormone therapy and diabetes on cataract |
| Q34444907 | Invited review: Pharmacogenetics of estrogen replacement therapy |
| Q34581841 | Is bio-identical hormone replacement therapy safer than traditional hormone replacement therapy?: a critical appraisal of cardiovascular risks in menopausal women |
| Q36349751 | Is there a link between oestrogen therapy and gallbladder disease? |
| Q34682870 | Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Position paper from the working group on coronary pathophysiology and microcirculation of the European Society of Cardiology |
| Q34714748 | Issues of hormone replacement therapy and cardiovascular disease for elderly women |
| Q33854590 | Lack of association of acute phase response proteins with hormone levels and antidepressant medication in perimenopausal depression |
| Q36364473 | Leptin, abdominal obesity, and onset of depression in older men and women |
| Q37307077 | Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the "timing hypothesis" |
| Q34257509 | Likelihood and predictors of ST-elevation in patients hospitalized for myocardial infarction |
| Q44642214 | Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). |
| Q24201974 | Long term hormone therapy for perimenopausal and postmenopausal women |
| Q24241279 | Long term hormone therapy for perimenopausal and postmenopausal women |
| Q24246577 | Long term hormone therapy for perimenopausal and postmenopausal women |
| Q30238978 | Long-term hormone therapy for perimenopausal and postmenopausal women |
| Q33910496 | Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses |
| Q36015213 | Low-dose estradiol and endothelial and inflammatory biomarkers in menopausal overweight/obese women |
| Q35605054 | MPA and postmenopausal coronary artery atherosclerosis revisited |
| Q57143367 | Management of the side effects of androgen deprivation therapy in men with prostate cancer |
| Q43846907 | Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal |
| Q35584010 | Mesenteric vein thrombosis associated with intravaginal contraceptives: a case report and review of the literature. |
| Q44770881 | Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? |
| Q42651095 | Mutuality's prospective beneficial effects on inflammation in female patients with rheumatoid arthritis |
| Q33677382 | Omega-3 fatty acids and cognitive function in women |
| Q44430829 | Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals |
| Q44244537 | Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women |
| Q51535496 | Oral contraceptive use and increased plasma concentration of C-reactive protein. |
| Q34283107 | Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes |
| Q47758018 | Periodontitis and atherogenesis: causal association or simple coincidence? |
| Q40565085 | Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. |
| Q36945220 | Post menopausal hormones and measures of subclinical atherosclerosis: the multi-ethnic study of atherosclerosis |
| Q46594043 | Post-menopausal hormone therapy and concentrations of protein C and antithrombin in elderly women |
| Q34037822 | Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy |
| Q34774237 | Postmenopausal hormone replacement therapy and atherosclerosis. |
| Q34482151 | Postmenopausal hormone replacement therapy as antiatherosclerotic therapy |
| Q36355137 | Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline |
| Q46144242 | Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus |
| Q42920313 | Prevention of coronary artery disease in men: Male hormone, female hormone, or both? |
| Q33857984 | Prevention of coronary heart disease. Part II. Secondary prevention, detection of subclinical disease, and emerging risk factors |
| Q37122524 | Primate models in women's health: inflammation and atherogenesis in female cynomolgus macaques (Macaca fascicularis) |
| Q44343973 | Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment |
| Q37291848 | Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners? |
| Q44489365 | Raloxifene, conjugated oestrogen and endothelial function in postmenopausal women |
| Q42618508 | Rationale, design and methods of the CASHMERE study. |
| Q44300805 | Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51. |
| Q46081928 | Relation between serum estradiol levels and mortality in postmenopausal female hemodialysis patients |
| Q61565678 | Relationship of total and abdominal adiposity with CRP and IL-6 in women |
| Q34919996 | Reproductive hormones and cardiovascular disease mechanism of action and clinical implications |
| Q37997819 | Respiratory health in women: from menarche to menopause |
| Q36300834 | Reverse cholesterol transport and cholesterol efflux in atherosclerosis |
| Q34707893 | Risk factors for coronary artery disease in women |
| Q28166927 | Role of C-reactive protein in cardiovascular disease |
| Q43758821 | Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women |
| Q34196350 | Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women |
| Q36185871 | Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke |
| Q96024722 | Sex-opposed inflammatory effects of 27-hydroxycholesterol are mediated via differences in estrogen signaling |
| Q46862477 | Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women |
| Q37427984 | Soy consumption, adhesion molecules, and pro-inflammatory cytokines: a brief review of the literature |
| Q36986116 | Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis |
| Q44684635 | The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics |
| Q35855883 | The cardiovascular effects of chronic hypoestrogenism in amenorrhoeic athletes: a critical review. |
| Q40439101 | The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women |
| Q34313804 | The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. |
| Q44205516 | The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial |
| Q46526827 | The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer |
| Q46958876 | The effects of cigarette smoking on C-reactive protein concentrations in men and women and its modification by exogenous oral hormones in women. |
| Q38482584 | The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study |
| Q46244173 | The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women |
| Q34421664 | The mechanisms of thrombotic risk induced by hormone replacement therapy |
| Q35085388 | The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women |
| Q74845460 | The relation of body fat mass and distribution to markers of chronic inflammation |
| Q45141243 | The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis |
| Q34011157 | The role of C-reactive protein in cardiovascular disease risk |
| Q35617189 | The role of estrogen in cardiovascular disease |
| Q44272957 | Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux |
| Q36665054 | Time-dependent behavioral, neurochemical, and metabolic dysregulation in female C57BL/6 mice caused by chronic high-fat diet intake. |
| Q28196757 | Utility of inflammatory markers in the management of coronary artery disease |
| Q37174271 | Vascular effects of estrogen and progestins and risk of coronary artery disease: importance of timing of estrogen treatment |
| Q35583311 | Vascular effects of estrogenic menopausal hormone therapy |
| Q73991166 | Vascular effects of estrogens: arterial protection versus venous thrombotic risk |
| Q37975897 | Vascular effects of glycoprotein130 ligands--part II: biomarkers and therapeutic targets |
| Q34514026 | Vascular inflammation as a therapeutic target for prevention of cardiovascular disease |
| Q35583454 | What is the influence of hormone therapy on homocysteine and crp levels in postmenopausal women? |
| Q74552962 | [C-reactive protein as a coronary risk factor] |
Search more.